Huqiao Games Establishes New Headquarters in Hong Kong, Appoints John Kavvouras as Managing Director
"Establishing our headquarters in Hong Kong positions us at the heart of Asia's gaming ecosystem, which is growing significantly faster than Western markets," says John Kavvouras, newly appointed Managing Director. "Hong Kong's proximity to key gaming markets provides the ideal platform to expand our services globally."
Mr. Kavvouras brings over 15 years of business experience to his role, with expertise in finance and emerging market development. His knowledge will be instrumental in developing new strategic initiatives to support the evolving needs of the gaming industry.
This transition also sees founder Wojtek Jaworski stepping into a new role, focusing on direct engagement with the dynamic Chinese gaming landscape, leveraging his deep understanding to foster innovation and growth.
"The future of gaming lies in Asia, where innovative monetization models, a massive user base, and a growing middle class create ideal conditions for growth," explains Mr. Kavvouras. "Our move to Hong Kong is a fundamental redirection of our strategy to better serve clients who are increasingly looking East for growth and inspiration."
The new headquarters will serve as the center of Huqiao Games' global operations. The firm plans to expand by recruiting local talent with experience in the Asian gaming market. Furthermore, Huqiao Games is actively seeking strategic partnerships with Chinese institutional investors to capitalize on the burgeoning PC gaming sector and empower Chinese developers to expand their reach globally.
About Huqiao Games
Founded in 2021, Huqiao Games specializes in helping Western game developers successfully enter Asian markets. The company has assisted over 96 studios from Europe and North America, including partnerships with Owlcat Games and Butterscotch Shenanigans.
Media Contact:
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,' report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC. DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment. The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment Oncolytic Virus Cancer Therapy Emerging Drugs Profile Olvi-Vec: Genelux Corporation Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer CAN-2409: Candel Therapeutics CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer. CG0070: CG Oncology CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer. Pelareorep: Oncolytics Biotech Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer. ParvOryx: Oryx GmbH ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer. SND005: Jiangsu Sinorda Biomedicine SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients. VCN-01: VCN Biosciences VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck. The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment. Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market. Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs Oncolytic Virus Cancer Therapy Companies Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intranasal Intravenous Oral Oral/Intravenous Parenteral Subcutaneous Subcutaneous/Intramuscular Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as Oncolytic Virus Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Oncolytic Virus Cancer Therapy Pipeline Report Coverage- Global Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies Table of Contents Introduction Executive Summary Oncolytic Virus Cancer Therapy: Overview Pipeline Therapeutics Therapeutic Assessment Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Olvi-Vec: Genelux Corporation Mid Stage Products (Phase II) SND005: Jiangsu Sinorda Biomedicine Early Stage Products (Phase I/II) AloCelyvir: Orgenesis Early Stage Products (Phase I) VCN-01: VCN Biosciences Preclinical and Discovery Stage Products SynOV 1.3: Beijing Syngentech Inactive Products Oncolytic Virus Cancer Therapy Key Companies Oncolytic Virus Cancer Therapy Key Products Oncolytic Virus Cancer Therapy- Unmet Needs Oncolytic Virus Cancer Therapy- Market Drivers and Barriers Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion Oncolytic Virus Cancer Therapy Analyst Views Oncolytic Virus Cancer Therapy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
5 hours ago
- Globe and Mail
Nasdaq Clings to Gains, New All-Time High Close
Tuesday, July 15, 2025 Markets wilted into the final minutes of trading before Tuesday's close, with only the tech-heavy Nasdaq staying in the green when the closing bell sounded. Off last Thursday's highs, the Nasdaq has once again led the way among major market indexes. The Dow dropped -498 points today, -0.98%, while the S&P 500 was -24 points, -0.40%. The Nasdaq gained +37 points, +0.18%, while the small-cap Russell 2000 slid a considerable -44 points, -1.99% for the session. NVIDIA NVDA closed at a new all-time high, +4% on the session and now +27% year to date, even with the big pullback in early April. The AI chip leader will soon be allowed to resume sales of its H20 AI chip in China; three months ago the government told the company it would need an additional license to do so. Crypto Week Hits Procedural Snag In what's being dubbed 'Crypto Week' on Capitol Hill, a procedural vote failed today, delaying the passage of key cryptocurrency allowances. Basically, certain Republicans in the House want to combine the three major crypto bills into one to put pressure on the Senate to pass all three, as well. But President Trump has already said he wants to pass the one piece of legislation of the three that is ready for his signature. J.B. Hunt Delivers Q2 Earnings Miss Arkansas-based transport services company J.B. Hunt JBHT delivered its third earnings miss in its last four quarters (9 of the last 12 quarters) in what has been a challenging industry for investors over the past few years. Earnings of $1.31 per share came in 3 cents lower than the Zacks consensus estimate (and a penny shy of the year-ago quarter), with revenues of $2.93 billion which matched the year-ago tally but was a tad light of the forecast $2.94 billion. Revenue performance gained on a +6% increase in its Intermodal business, and +13% on truckloads (strictly limited to JBT). Yet Operating Income slipped -4%to $197.3 million in the quarter. Shares are down -3% on the news, -12% year to date. The stock carried a Zacks Rank #4 (Sell) rating into today's earnings report. (You can see the full Zacks Earnings Calendar here.) What to Expect from the Stock Market Wednesday While this morning's CPI report for June gave us insights into the retail sector last month, Wednesday morning brings us the wholesale print: the Producer Price Index (PPI). Last month, ahead of tariff manifestations in the marketplace, headline PPI was +2.6% year over year, +2.7% on core. If we see the same jump we did in this morning's CPI numbers, we could see ourselves back at a '3-handle' on wholesale prices, further inflating the cost of goods. We'll also see plenty more Q2 earnings reports tomorrow, including financials Bank of America BAC, Morgan Stanley MS and Goldman Sachs GS and airline major United Airlines UAL. We're still just ramping up on earnings, however; by next week, we'll see days where more than 200 companies are reporting quarterly results. Questions or comments about this article and/or author? Click here>> 7 Best Stocks for the Next 30 Days Just released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops." Since 1988, the full list has beaten the market more than 2X over with an average gain of +23.5% per year. So be sure to give these hand picked 7 your immediate attention. See them now >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Goldman Sachs Group, Inc. (GS): Free Stock Analysis Report Bank of America Corporation (BAC): Free Stock Analysis Report Morgan Stanley (MS): Free Stock Analysis Report United Airlines Holdings Inc (UAL): Free Stock Analysis Report J.B. Hunt Transport Services, Inc. (JBHT): Free Stock Analysis Report NVIDIA Corporation (NVDA): Free Stock Analysis Report
CTV News
6 hours ago
- CTV News
Crypto week legislation hits snag in U.S. Congress, some stocks fall
An advertisement for the cryptocurrency, Bitcoin, is displayed on a building in Hong Kong on Nov. 18, 2021. (AP Photo/Kin Cheung, File) The fate of long-awaited cryptocurrency legislation in the U.S. Congress was cast into doubt Tuesday, as a procedural vote to consider the measures was shot down by lawmakers from both parties, and shares of some companies in the sector fell. House Republicans had billed this week as 'Crypto week,' and were keen to advance numerous pieces of legislation aimed at providing clarity to the digital asset industry and long-sought legitimacy to the sector. But those efforts hit an early snag on Tuesday, when several conservative Republicans joined with Democrats in blocking a procedural vote to allow consideration of three crypto bills as part of a dispute over how the measures should be packaged and considered. Shortly after the vote, House Speaker Mike Johnson told reporters that he planned to continue discussing the matter with members and hoped to vote on it again shortly. Shares of crypto-related stocks including Circle Internet and Coinbase Global dropped on the news but then pared losses. Circle Internet fell over 4 per cent while Coinbase was down 1.5 per cent. The House was attempting to pass a series of crypto-related bills, most notably a bill that would establish a regulatory framework for stablecoins. Stablecoins, a type of cryptocurrency designed to maintain a constant value, usually a 1:1 dollar peg, are commonly used by crypto traders to move funds between tokens. Their use has grown rapidly in recent years, and proponents say they could be used to send payments instantly. That bill -- and another the House is considering that would define when a crypto token is a commodity -- would be a huge win for the crypto industry. The House also was set to consider a bill that would prohibit the U.S. from issuing a central bank digital currency. Republicans say there is a risk this could give the government too much control over Americans' personal finances. That bill has not been considered in the Senate and the Federal Reserve has not indicated a desire to develop a central bank digital currency. --- Reporting by Chris Prentice and Caroline Valetkevitch; editing by Pete Schroeder and David Gregorio
